Drug
Etesevimab clinical trials
Also written LY3832479 and LY-CoV016.
- studies test it
- 7
- open now
- 0
- in phase 3
- 2
- first study started
- 2020
How studies write it
Studies that test it under each name
Name
Studies by the year they started
7 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 2020 | 6 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Eli Lilly and Company (5) · Peking Union Medical College Hospital (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses etesevimab is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2/3Eli Lilly and CompanyNCT04427501Written as LY3832479
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2Eli Lilly and CompanyNCT04634409Written as Etesevimab
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and StaffCompletedPhase 3Eli Lilly and CompanyNCT04497987Written as Etesevimab
- A Study of LY3832479 (LY-CoV016) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04441931Written as LY3832479
- A Study of LY3832479 (LY-CoV016) in Healthy Participants 1CompletedPhase 1Eli Lilly and CompanyNCT04611789Written as LY3832479
- Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)Status unknownPhase 2Peking Union Medical College HospitalNCT04931238Written as JS016
- Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health SubjectsStatus unknownPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT04441918Written as JS016 (anti-SARS-CoV-2 monoclonal antibody)
Codes
What other systems call etesevimab · ClinicalTrials.gg INT001487
- MeSH (NLM) C000711968etesevimabOne source NLM
- UNII (FDA) N7Q9NLF11IETESEVIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2477854Confirmed FDA, Wikidata
- Wikidata Q105535482etesevimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C173977EtesevimabOne source FDA
- DrugBank DB15897One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711968 | etesevimab | One source NLM |
| UNII (FDA) | N7Q9NLF11I | ETESEVIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2477854 | — | Confirmed FDA, Wikidata |
| Wikidata | Q105535482 | etesevimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C173977 | Etesevimab | One source FDA |
| DrugBank | DB15897 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.